Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

T Fujino, K Suda, T Mitsudomi - Expert opinion on emerging drugs, 2020 - Taylor & Francis
Introduction MET aberrations, including MET exon 14 skipping mutation and amplification,
are present in~ 5% of non-small cell lung cancer (NSCLC) cases, and these levels are …
被引用次数：40 相关文章

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

T Fujino, K Suda, T Mitsudomi - Expert opinion on …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction MET aberrations, including MET exon 14 skipping mutation and amplification,
are present in~ 5% of non-small cell lung cancer (NSCLC) cases, and these levels are …

[引用][C] Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

T Fujino, K Suda, T Mitsudomi - Expert Opinion on Emerging Drugs, 2020 - cir.nii.ac.jp
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

T Fujino, K Suda, T Mitsudomi - Expert Opinion on Emerging Drugs, 2020 - europepmc.org
Introduction MET aberrations, including MET exon 14 skipping mutation and amplification,
are present in~ 5% of non-small cell lung cancer (NSCLC) cases, and these levels are …